hotspot -WSS

hotspot

author：knowledge 2025-09-29 21:14:32 - browse：62336

Warning sign illustration made of 0s and 1s. -- first opinion coverage from sTAT — Adobe

Big businesses poised to profit from the advance of artificial intelligence in health care are pushing back against newly proposed federal rules meant to increase oversight and fairness of AI tools used to help make decisions about patient care.

The opposition, which includes Google and Amazon as well as large health care providers, insurers, and medical software vendors, is focused on an attempt to put tighter guardrails around the use of AI by the Office of the National Coordinator for Health Information Technology.

The agency wants to require developers of electronic health records and other health software to provide users with details about the training and testing of predictive models that draw data from their systems, or are hosted within them. It also wants developers to assess and publicly disclose potential risks and create a way for clinicians and other users to report problems.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： New guidelines on severe brain injury complicate already difficult decisions

WSS

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

FDA rejects Alnylam's heart disease treatment over insufficient data

AI can decode, harness the power of the humane immune system

Histogen: Failed biotech offers rare public look inside

Ask STAT: What do you want to know about ChatGPT in medicine?

New guidelines on severe brain injury complicate already difficult decisions

hotspot

hotspot

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

AI can decode, harness the power of the humane immune system

Trump demands the U.S. pay no more for drugs than other countries … again

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

In areas with more Black doctors, Black people live longer

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Liquid biopsy for lung cancer is launched by Delfi

focus

Chemotherapy drug shortage eases slightly but still widespread

The science behind Janet Jackson's pregnancy at 49

FDA rejects Alnylam's heart disease treatment over insufficient data

FDA panel signals lack of confidence in Amgen cancer drug data

Was Amgen transparent enough on FDA's concern on cancer drug?

Colonoscopy at 40? Study finds a possible benefit

entertainment

hotspot

hotspot

explore